Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.
about
Chimeric Antigen Receptors Modified T-Cells for Cancer TherapyCAR T Cell Therapy: A Game Changer in Cancer TreatmentCancer Precision Medicine in China.Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemiaCocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma.Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.Gene therapy research in Asia.Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo.Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment.Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment.An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts"Neurological complications of new chemotherapy agents".CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Posttransplant chimeric antigen receptor therapy.Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantaStop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models.Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis.Armed T cells with CAR for cancer immunotherapy.Blinatumomab bridges the gap between leukemia and immunity.CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial.Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T CellsExtramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case reportThe efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysisThe biological basis and clinical symptoms of CAR-T therapy-associated toxicites
P2860
Q26773309-975F8B18-F650-4DCF-ABDE-4B9FCB68A3B7Q26822769-413D6A7C-4619-4FBA-BEFC-D5EC2EB31ECCQ37390525-AC878A7F-D5C8-45F9-9509-D53AECBDBF64Q37442731-DD3BDFCD-2DD6-481D-8FBE-490F9162A8B1Q37566921-CED7A9F3-24EF-46FE-9837-8D7413C96973Q37576835-882FDB51-9CA8-4DCE-9660-3726732DB652Q37609801-DB014673-CDFB-4B69-9AF5-CE26AB85D8FAQ38654544-40AD0E2D-847B-4DCE-B5DF-795D54E83C4BQ38677904-8C79E867-3F6F-4698-89D9-44FADC1B0CDDQ38747333-6FFF401E-745E-4D19-B6F8-6D0C3564C899Q38786626-486B02C6-AD01-4596-9607-59BF9953239DQ38913549-A1040473-2BFA-4DA8-8936-065485A1E872Q39106490-50986474-F1FD-4988-8999-69D3086E247BQ39177087-45AA0F31-9A05-4F94-852B-6F184A61FFD2Q39280002-21C988F8-1BE3-4801-B6A3-AA16A7506490Q39893104-57926E34-801F-4DCC-8E44-1DA44B7BDCAEQ41600980-E9AFB434-843F-4943-8E83-DD2EB6E65CD0Q45069581-E43F5B42-E02B-4101-8B32-ECFB0E6CE2D2Q46018826-98218EE9-EDCB-4479-9307-6117B59FC5DCQ47325431-2FA937A1-3417-4E1D-88DA-77F94310F6CEQ47550219-0A9B5328-AE86-49D8-B4C7-90B1B4CCF6AAQ47596812-930E7F6E-E606-404E-B9A7-BA01B3B2F684Q47855599-2A7B1F9F-AAB2-4C5D-BFD6-8F91192AF51EQ49477144-B4AFBD2C-8390-4D7F-BAD6-619F6A93A861Q49878390-E2C7DF9D-862F-4BD2-9FD2-B996BFAA1A90Q50027149-AA1B3943-250E-4A97-B9CB-B0361B2774BDQ50042504-15103A2B-91D1-4B89-B40A-ADDB6C27DF76Q52780150-6C24E54A-DAE7-4555-A659-7DA56BD5CD84Q55477963-767272A1-CBC9-40E3-B8A5-1B4D0A4A3A14Q57173949-5A3751DC-2652-4334-BBD5-D1243908319EQ57490418-55EF5A85-DF59-41AA-A3E6-30470C06DBA7Q58695003-7C53BDC3-E0D2-45AD-80DE-899D70DADC99Q58765358-251009D6-0C3E-4CE4-B7DB-3A3F052595C8
P2860
Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Tolerance and efficacy of auto ...... with extramedullary leukemia.
@ast
Tolerance and efficacy of auto ...... with extramedullary leukemia.
@en
type
label
Tolerance and efficacy of auto ...... with extramedullary leukemia.
@ast
Tolerance and efficacy of auto ...... with extramedullary leukemia.
@en
prefLabel
Tolerance and efficacy of auto ...... with extramedullary leukemia.
@ast
Tolerance and efficacy of auto ...... with extramedullary leukemia.
@en
P2093
P2860
P1433
P1476
Tolerance and efficacy of auto ...... with extramedullary leukemia.
@en
P2093
Chunmeng Wang
Fengxia Shi
Hanren Dai
Hongli Zhu
Kaichao Feng
Meixia Chen
Qingwang Han
Quanshun Wang
Weidong Han
P2860
P304
P356
10.1080/2162402X.2015.1027469
P577
2015-05-26T00:00:00Z